Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gptkb:monoclonal_antibody |
| gptkbp:administeredBy |
subcutaneous injection
|
| gptkbp:approvalYear |
2022
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L01FX24
|
| gptkbp:brand |
Tecvayli
|
| gptkbp:CASNumber |
2228321-98-8
|
| gptkbp:developer |
gptkb:Janssen
|
| https://www.w3.org/2000/01/rdf-schema#label |
teclistamab
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
bispecific antibody
redirects T cells to kill myeloma cells |
| gptkbp:routeOfAdministration |
subcutaneous
|
| gptkbp:sideEffect |
infections
neutropenia cytokine release syndrome |
| gptkbp:target |
gptkb:BCMA
|
| gptkbp:usedFor |
multiple myeloma
|
| gptkbp:bfsParent |
gptkb:L01XC43
|
| gptkbp:bfsLayer |
7
|